GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer.
O'Kane, Grainne M
GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer. [electronic resource] - Clinical cancer research : an official journal of the American Association for Cancer Research 09 2020 - 4901-4910 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1557-3265
10.1158/1078-0432.CCR-19-3724 doi
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols--pharmacology
Carcinoma, Pancreatic Ductal--drug therapy
Drug Resistance, Neoplasm--genetics
Female
Fluorouracil--pharmacology
GATA6 Transcription Factor--analysis
Gene Expression Regulation, Neoplastic
Humans
Irinotecan--pharmacology
Leucovorin--pharmacology
Male
Middle Aged
Multicenter Studies as Topic
Oxaliplatin--pharmacology
Pancreatic Neoplasms--drug therapy
Prognosis
Prospective Studies
RNA-Seq
Response Evaluation Criteria in Solid Tumors
GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer. [electronic resource] - Clinical cancer research : an official journal of the American Association for Cancer Research 09 2020 - 4901-4910 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1557-3265
10.1158/1078-0432.CCR-19-3724 doi
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols--pharmacology
Carcinoma, Pancreatic Ductal--drug therapy
Drug Resistance, Neoplasm--genetics
Female
Fluorouracil--pharmacology
GATA6 Transcription Factor--analysis
Gene Expression Regulation, Neoplastic
Humans
Irinotecan--pharmacology
Leucovorin--pharmacology
Male
Middle Aged
Multicenter Studies as Topic
Oxaliplatin--pharmacology
Pancreatic Neoplasms--drug therapy
Prognosis
Prospective Studies
RNA-Seq
Response Evaluation Criteria in Solid Tumors